Burning Rock

Hengrui's MSCI ESG Rating Upgraded to A

Hengrui, as one of the leading pharmaceutical companies in innovation, has achieved continuous improvement in its MSCI ESG rating to "A" level, placing it at the forefront of the pharmaceutical industry in China.

Lanja has completed the Series A funding of hundred millions CNY

Shanghai Lanja Medical Technology Co., Ltd (“Lanja”) recently has announced the completion of the Series A funding of hundred millions CNY.

RabPharma has completed the Series A+ funding of hundred millions CNY

Zhongshan RabPharma Biopharmaceutical Co., Ltd. (“RabPharma”) recently has announced the completion of the Series A+ funding of hundred millions CNY.

Powertight has completed a pre-Series A funding of hundred millions CNY

Powertight Biotechnology (Hangzhou) Co., Ltd. (“Powertight”) recently has announced the completion of a pre-Series A funding of hundred millions CNY.

Foremed Legend has completed the pre-Series A+ funding

Suzhou Foremed Legend Medical Technology Company, Ltd. (“Foremed Legend”) recently has announced the completion of pre-Series A+ funding.

Bioprofile completed a Series A funding of hundred millions CNY

Shanghai Bioprofile Technology Company, Ltd. (“Bioprofile”) recently has announced the completion of hundred millions of CNY in Series A funding.

CSH Medical completed a Series A+ funding of nearly one hundred million CNY

CSH Medical Equipment (Shanghai) Co., Ltd (“CSH Medical”) recently has announced the completion of nearly one hundred million CNY in Series A+ funding.

Mateside has completed the first round of financing

Zhejiang Mateside Medical Device Technology Co., Ltd. (“Mateside”) recently has announced the completion of the first round of nearly 100 million CNY financing.

Milestone Biotech has completed a Series A funding of over a hundred million CNY

Milestone Biotechnologies Co., Ltd. (“Milestone Biotech”) recently has announced the completion of a Series B2 funding of over a hundred million CNY.

Bostal has completed a Series B2 funding of hundred millions CNY

Bostal Drug Delivery Co., Ltd. (“Bostal”) recently has announced the completion of a Series B2 funding of hundred millions CNY.

AI Pharmaceutical R&D Company DP Technology Raises New Round of Over CNY 700 Mn Financing

EqualOcean has learned that DP Technology（深势科技）, an AI pharmaceutical research company, has recently successfully completed a funding round of over CNY 700 million. Investors in this round include Zhongyuan Capital（众源资本）, MSA Capital（和玉资本）, Loyal Valley Capital（正心谷资本）, Evergreen Scitech Delta（深势科技）, and many other industry-specific investors, with Lighthouse Capital（光源资本） serving as the exclusive financial advisor.

Saints Sages has completed the Series B funding

Shanghai Saints Sages Surgical Co., Ltd. (“Saints Sages”) recently has announced the completion of the Series B funding, Qiming Venture Partners (启明创投) is the largest institutional investor.

Cascade completed a Series A funding of 140 million CNY

Cascade (Shanghai) Pharmaceutical, Inc (“Cascade”) recently announced the completion of 140 million CNY in Series A funding.

Neurophth Completes C+ Round Financing of Nearly RMB 700 Mn

On August 9, 2023, China's leading gene therapy company specializing in ophthalmic diseases, Neurophth (纽福斯), announced the completion of a C+ round of financing of nearly CNY 700 million.

Chinese Reproductive Anti-aging Brand DACHAO Gains Favor from Capital in Swiss

Recently, Hainan Leyun Biotechnology Co., Ltd. (海南乐孕生物科技有限公司) received CNY tens of millions in Series B financing, and the investor is the Swiss global financial group Cedrus Investment.

US Vaccine Manufacturer Moderna Makes Its First Investment in China

American vaccine manufacturer Moderna announced a major decision.

ChromX completed a pre-Series A funding of ten millions CNY

ChromX Health (“ChromX”) recently has announced the completion of ten millions of CNY in pre-Series A funding, Funsun Capital (复星创富) was the largest institutional investor.

Forward Pharma completed a Series A+ funding of ten millions CNY

Shenzhen Forward Pharmaceutical Co., Ltd (“Forward Pharma”) recently has announced the completion of ten millions of CNY in Series A+ funding.

Yun Nan Bai Yao's performance in the first half of the year is expected to increase

Chinese Sports Tech Brand Keep Officially Lists on the Hong Kong Stock Exchange

On July 12, 2023, Beijing-based Beijing Calorie Technology Co., Ltd (hereinafter referred to as "Keep") was officially listed on the Hong Kong Stock Exchange (HKEx) under the stock code "3650" at an offering price of HKD 28.92 per share.